8-K: Co-Diagnostics Withdraws FDA Submission for COVID-19 Test, Plans Enhanced Version

Co-Diagnostics withdraws its 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro following FDA feedback, opting to submit an enhanced version for clearance.

Summary

• Co-Diagnostics has withdrawn its 510(k) application to the FDA for its Co-Dx PCR COVID-19 Test on the PCR Pro.
• The decision was made after discussions with the FDA regarding the shelf-life stability of a test component.
• The company plans to submit an enhanced version of the test for 510(k) OTC clearance.
• This new submission will incorporate more recent Co-Dx PCR platform developments.
• The company expects to follow the COVID-19 test with additional tests for tuberculosis, upper-respiratory multiplex, and a multiplex HPV test.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the withdrawal of the FDA submission is a setback, the company is taking proactive steps to address the issues and resubmit an enhanced version of the test. The company also highlights positive engagement with the FDA and good test performance in clinical evaluations.

Positives

• Co-Diagnostics had a productive engagement with the FDA regarding the initial regulatory submission.
• The company's test performed well in clinical evaluations, including performance data and functionality of the instrument.
• The company believes the enhanced version of the test will address the FDA's concerns and improve operational efficiencies.
• The company plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance.
• The company plans to develop additional tests for tuberculosis, upper-respiratory multiplex, and a multiplex HPV test.

Negatives

• The company withdrew its 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro.
• The withdrawal was due to FDA feedback regarding shelf-life stability of a test component, indicating a potential issue with the initial test design.

Risks

• The Co-Dx PCR platform is subject to review by the FDA and/or other regulatory bodies and is not available for sale.
• There is no assurance that the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties.
• The company's future results are subject to inherent uncertainties, risks, and changes in circumstances.

Future Outlook

Co-Diagnostics plans to submit an enhanced version of its Co-Dx PCR COVID-19 test for 510(k) OTC clearance and expects to follow it with additional tests for tuberculosis, upper-respiratory multiplex, and a multiplex HPV test.

Management Comments

• Co-Dx is pleased with the productive engagement with the FDA related to the initial regulatory submission and with the performance of the test in clinical evaluations, including performance data and functionality of the instrument.
• Co-Dx has determined that the best long-term solution would be to submit a version of the test that has been enhanced to address the matter raised in the 510(k) review process.

Industry Context

The announcement reflects the ongoing regulatory scrutiny and iterative development process common in the medical diagnostics industry, particularly for COVID-19 related tests. Companies must continuously adapt their products based on regulatory feedback and evolving scientific understanding.

Comparison to Industry Standards

• The 510(k) clearance process is a standard pathway for medical devices, including diagnostic tests, to gain FDA approval in the United States.
• Shelf-life stability is a critical factor in the FDA's review of diagnostic tests, and companies must demonstrate that their products maintain their performance characteristics over time.
• Other molecular diagnostics companies, such as Roche, Abbott, and Thermo Fisher Scientific, also undergo similar regulatory processes for their diagnostic products.

Stakeholder Impact

• Shareholders may experience short-term disappointment due to the delay in FDA clearance.
• Customers may experience a delay in the availability of the Co-Dx PCR COVID-19 Test on the PCR Pro.
• Employees may be involved in the development and submission of the enhanced version of the test.

Next Steps

• Co-Diagnostics plans to collect clinical evaluation data to support the new test's performance.
• Co-Diagnostics plans to submit the next iteration of the Co-Dx PCR COVID-19 test for 510(k) OTC clearance.
• Co-Diagnostics plans to develop additional tests for tuberculosis, upper-respiratory multiplex, and a multiplex HPV test.

Key Dates